18 Facts About Aripiprazole


Aripiprazole, sold under the brand names Abilify and Aristada among others, is an atypical antipsychotic.

FactSnippet No. 626,612

Aripiprazole was approved for medical use in the United States in 2002.

FactSnippet No. 626,613

Aripiprazole is primarily used for the treatment of schizophrenia or bipolar disorder.

FactSnippet No. 626,614

Aripiprazole is effective for the treatment of acute manic episodes of bipolar disorder in adults, children, and adolescents.

FactSnippet No. 626,615

Aripiprazole is an effective add-on treatment for major depressive disorder; however, there is a greater rate of side effects such as weight gain and movement disorders.

FactSnippet No. 626,616

Related searches

United States ADHD FDA

Aripiprazole is not currently approved for the treatment of OCD and is instead used off-label for this indication.

FactSnippet No. 626,617

Aripiprazole has been reported to provide some benefit in improving cognitive functioning in people with ADHD without other psychiatric comorbidities, though the results have been disputed.

FactSnippet No. 626,618

Aripiprazole was discovered in 1988 by scientists at the Japanese firm Otsuka Pharmaceutical.

FactSnippet No. 626,619

Aripiprazole is a partial agonist of the serotonin 5-HT1A receptor.

FactSnippet No. 626,620

Aripiprazole was frequently found to be a partial agonist, with an intrinsic activity that could be low, intermediate, or high.

FactSnippet No. 626,621

Aripiprazole has a favorable pharmacological profile in being a 5-HT2A antagonist and a 5-HT2C partial agonist.

FactSnippet No. 626,622

Aripiprazole is a phenylpiperazine and is chemically related to nefazodone, etoperidone, and trazodone.

FactSnippet No. 626,623

Aripiprazole was discovered by scientists at Otsuka Pharmaceutical and was called OPC-14597.

FactSnippet No. 626,624

Aripiprazole has been approved by the FDA for the treatment of both acute manic and mixed episodes, in people older than ten years.

FactSnippet No. 626,625

Aripiprazole has been described as the prototypical third-generation antipsychotic, as opposed to first-generation antipsychotics like haloperidol and second-generation antipsychotics like clozapine.

FactSnippet No. 626,626

Aripiprazole was under development for the treatment of attention-deficit hyperactivity disorder, but development for this indication was discontinued.

FactSnippet No. 626,627

Aripiprazole has been studied for the treatment of amphetamine dependence and other substance use disorders, but more research is needed to support aripiprazole for these potential uses.

FactSnippet No. 626,628

Aripiprazole is under development for the treatment of agitation and pervasive child development disorders.

FactSnippet No. 626,629